FI940807A - Peptidejä, joilla on kasvuhormonia vapauttavaa aktiivisuutta - Google Patents

Peptidejä, joilla on kasvuhormonia vapauttavaa aktiivisuutta Download PDF

Info

Publication number
FI940807A
FI940807A FI940807A FI940807A FI940807A FI 940807 A FI940807 A FI 940807A FI 940807 A FI940807 A FI 940807A FI 940807 A FI940807 A FI 940807A FI 940807 A FI940807 A FI 940807A
Authority
FI
Finland
Prior art keywords
peptides
growth hormone
releasing activity
releasing
activity
Prior art date
Application number
FI940807A
Other languages
English (en)
Swedish (sv)
Other versions
FI940807A0 (fi
FI120095B (fi
Inventor
Cyril Y Bowers
David Coy
Original Assignee
Univ Tulane
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Tulane filed Critical Univ Tulane
Publication of FI940807A0 publication Critical patent/FI940807A0/fi
Publication of FI940807A publication Critical patent/FI940807A/fi
Application granted granted Critical
Publication of FI120095B publication Critical patent/FI120095B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/60—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
FI940807A 1991-08-22 1994-02-21 Menetelmä peptidien valmistamiseksi, joilla on kasvuhormonia vapauttavaa aktiivisuutta FI120095B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US74835091 1991-08-22
US07/748,350 US5663146A (en) 1991-08-22 1991-08-22 Polypeptide analogues having growth hormone releasing activity
PCT/US1992/007026 WO1993004081A1 (en) 1991-08-22 1992-08-20 Peptides having growth hormone releasing activity
US9207026 1992-08-20

Publications (3)

Publication Number Publication Date
FI940807A0 FI940807A0 (fi) 1994-02-21
FI940807A true FI940807A (fi) 1994-02-21
FI120095B FI120095B (fi) 2009-06-30

Family

ID=25009088

Family Applications (2)

Application Number Title Priority Date Filing Date
FI940807A FI120095B (fi) 1991-08-22 1994-02-21 Menetelmä peptidien valmistamiseksi, joilla on kasvuhormonia vapauttavaa aktiivisuutta
FI20050467A FI120691B (fi) 1991-08-22 2005-05-02 Ei-terapeuttinen menetelmä kasvuhormonin vapautumisen edistämiseksi eläimessä

Family Applications After (1)

Application Number Title Priority Date Filing Date
FI20050467A FI120691B (fi) 1991-08-22 2005-05-02 Ei-terapeuttinen menetelmä kasvuhormonin vapautumisen edistämiseksi eläimessä

Country Status (26)

Country Link
US (2) US5663146A (fi)
EP (1) EP0605484B1 (fi)
JP (1) JP3179489B2 (fi)
KR (1) KR100247212B1 (fi)
CN (1) CN1035256C (fi)
AT (1) ATE172742T1 (fi)
AU (1) AU666673B2 (fi)
BG (1) BG62655B1 (fi)
BR (2) BR9206398A (fi)
CA (1) CA2116120C (fi)
CZ (1) CZ293281B6 (fi)
DE (1) DE69227462T2 (fi)
DK (1) DK0605484T3 (fi)
ES (1) ES2124263T3 (fi)
FI (2) FI120095B (fi)
HU (1) HU223664B1 (fi)
IL (1) IL102848A (fi)
MX (1) MX9204861A (fi)
NO (1) NO314695B1 (fi)
NZ (1) NZ244034A (fi)
PL (1) PL169562B1 (fi)
RO (1) RO112507B1 (fi)
RU (1) RU2126014C1 (fi)
SK (1) SK282895B6 (fi)
WO (1) WO1993004081A1 (fi)
ZA (1) ZA926337B (fi)

Families Citing this family (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0698015A1 (en) 1993-05-14 1996-02-28 Genentech, Inc. Preparation of n-cyanodithioimino-carbonates and 3-mercapto-5-amino-1h-1,2,4-triazole
UA42747C2 (uk) * 1993-12-23 2001-11-15 Ново Нордіск А/С Похідні пептиду,фармацевтична композиція та спосіб стимулювання секреції гормону росту
HU221092B1 (en) * 1993-12-23 2002-08-28 Novo Nordisk As Compounds with growth hormone releasing properties
US20020111461A1 (en) * 1999-05-21 2002-08-15 Todd C. Somers Low molecular weight peptidomimetic growth hormone secretagogues
US5798337A (en) * 1994-11-16 1998-08-25 Genentech, Inc. Low molecular weight peptidomimetic growth hormone secretagogues
HUP9802821A3 (en) * 1995-06-22 2000-03-28 Novo Nordisk As Compounds with growth hormone releasing properties
CN1127488C (zh) * 1996-04-24 2003-11-12 诺沃挪第克公司 具有生长激素释放特性的化合物
US6127341A (en) * 1997-06-20 2000-10-03 Novo Nordisk A/S Compounds with growth hormone releasing properties
AU7906998A (en) 1997-06-20 1999-01-04 Novo Nordisk A/S Compounds with growth hormone releasing properties
ZA987383B (en) * 1997-08-19 2000-02-17 Lilly Co Eli Treatment of congestive heart failure with growth hormone secretagogues.
US6329342B1 (en) 1997-08-19 2001-12-11 Eli Lilly And Company Treatment of congestive heart failure with growth hormone secretagogues
EP1506969B1 (en) 1998-01-16 2010-06-09 Helsinn Therapeutics (U.S.), Inc. Compounds with growth hormone releasing properties
WO1999039730A1 (fr) * 1998-02-09 1999-08-12 Kaken Pharmaceutical Co., Ltd. Preparation a administration orale contenant des peptides favorisant la secretion d'hormone de croissance
US6919315B1 (en) 1998-06-30 2005-07-19 Novo Nordisk A/S Compounds with growth hormone releasing properties
US6682908B1 (en) 1998-07-10 2004-01-27 Merck & Co., Inc. Mouse growth hormone secretagogue receptor
CA2333857A1 (en) 1998-07-13 2000-01-20 Merck & Co., Inc. Growth hormone secretagogue related receptors and nucleic acids
EP1112282A4 (en) 1998-08-10 2002-10-31 Merck & Co Inc RECEPTOR OF THE GROWTH HORMONE SECRETION PROMOTER FROM THE DOG
AU5671099A (en) 1998-08-14 2000-03-06 The Administrators Of The Tulane Eductional Fund Compounds having growth hormone releasing activity
US6639076B1 (en) 1998-08-18 2003-10-28 Eli Lilly And Company Growth hormone secretagogues
US6696063B1 (en) 1998-12-30 2004-02-24 Applied Research Systems Ars Holding N.V. Treatment of HIV-associated dysmorphia/dysmetabolic syndrome (HADDS) with or without lipodystrophy
US7022677B1 (en) 1999-02-18 2006-04-04 Kaken Pharmaceutical Co., Ltd. Amide derivatives as growth hormone secretagogues
EP1158996A4 (en) * 1999-02-18 2005-01-12 Kaken Pharma Co Ltd NEW AMID DERIVATIVES AS GROWTH HORMONE SECRETION CONVEYORS
US6828331B1 (en) 1999-02-19 2004-12-07 Eli Lilly And Company Growth hormone secretagogues
US20040192593A1 (en) * 1999-07-26 2004-09-30 Baylor College Of Medicine Protease resistant ti-growth hormone releasing hormone
AU772752B2 (en) 1999-07-26 2004-05-06 Baylor College Of Medicine Super-active porcine growth hormone releasing hormone analog
AU7685200A (en) * 1999-10-12 2001-04-23 Kaken Pharmaceutical Co., Ltd. Powdery inhalational preparations and process for producing the same
UA73530C2 (uk) 1999-11-10 2005-08-15 Ново Нордіск А/С Сполука з властивостями вивільнювати гормон росту
JP3498041B2 (ja) * 2000-05-29 2004-02-16 科研製薬株式会社 プラルモレリン含有点鼻用製剤
ES2333097T3 (es) 2000-05-31 2010-02-17 Raqualia Pharma Inc Uso de secretagogos de la hormona de crecimiento para estimular la motilidad gastrointestinal.
US7645898B2 (en) 2000-08-24 2010-01-12 University Of Tennessee Research Foundation Selective androgen receptor modulators and method of use thereof
US7919647B2 (en) 2000-08-24 2011-04-05 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US7622503B2 (en) 2000-08-24 2009-11-24 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US7855229B2 (en) 2000-08-24 2010-12-21 University Of Tennessee Research Foundation Treating wasting disorders with selective androgen receptor modulators
CA2435563A1 (en) 2001-02-02 2002-08-15 Conjuchem Inc. Long lasting growth hormone releasing factor derivatives
US7125840B2 (en) * 2001-10-09 2006-10-24 Eli Lilly And Company Substituted dipeptides as growth hormone secretagogues
CN100417419C (zh) * 2001-10-26 2008-09-10 贝勒医学院 改变个体的瘦体重和骨特性的组合物和方法
US8853266B2 (en) 2001-12-06 2014-10-07 University Of Tennessee Research Foundation Selective androgen receptor modulators for treating diabetes
US6831102B2 (en) 2001-12-07 2004-12-14 Bristol-Myers Squibb Company Phenyl naphthol ligands for thyroid hormone receptor
MY142457A (en) 2001-12-11 2010-11-30 Advisys Inc Plasmid mediated supplementation for treating chronically ill subjects
US7015219B2 (en) 2001-12-19 2006-03-21 Bristol-Myers Squibb Company 3-aryl-hydroxybenzoxazines and 3, 4-dihydro-3-aryl-hydroxybenzoxazines as selective estrogen receptor beta modulators
AR038816A1 (es) * 2002-02-07 2005-01-26 Baylor College Medicine Desarrollo modificado de la glandula pituitaria en la progenie de las hembras prenadas tratadas con terapia con la hormona liberadora de la hormona de crecimiento
US7772433B2 (en) 2002-02-28 2010-08-10 University Of Tennessee Research Foundation SARMS and method of use thereof
US7381730B2 (en) 2002-03-15 2008-06-03 Bristol-Myers Squibb Company 3-arylquinazoline derivatives as selective estrogen receptor beta modulators
US20060167268A1 (en) * 2002-04-09 2006-07-27 Eli Lilly And Company, Patent Division, Growth hormone secretagogues
ATE338767T1 (de) * 2002-04-09 2006-09-15 Lilly Co Eli Dipeptidische wachstumshormonsekretionsförderern
AU2003225305A1 (en) 2002-05-08 2003-11-11 Bristol-Myers Squibb Company Pyridine-based thyroid receptor ligands
US7405234B2 (en) 2002-05-17 2008-07-29 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
JP2005539091A (ja) 2002-08-23 2005-12-22 バラリゼーション−ラシェアシェイ ソサイテ エン コマンディテ アテローム性動脈硬化および高コレステロール血症の治療または予防における成長ホルモン放出ペプチド類
EP1567487A4 (en) 2002-11-15 2005-11-16 Bristol Myers Squibb Co OPEN-CHAINED, PROLYL-FROSTED MODULATORS OF ANDROGEN RECEPTOR FUNCTION
US8309603B2 (en) 2004-06-07 2012-11-13 University Of Tennessee Research Foundation SARMs and method of use thereof
TW200504021A (en) 2003-01-24 2005-02-01 Bristol Myers Squibb Co Substituted anilide ligands for the thyroid receptor
WO2004069793A2 (en) 2003-01-28 2004-08-19 Bristol-Myers Squibb Company Novel 2-substituted cyclic amines as calcium sensing receptor modulators
CA2513743C (en) * 2003-01-28 2013-06-25 Advisys, Inc. Reducing culling in herd animals growth hormone releasing hormone (ghrh)
US7205322B2 (en) 2003-02-12 2007-04-17 Bristol-Myers Squibb Company Thiazolidine compounds as calcium sensing receptor modulators
US7557143B2 (en) 2003-04-18 2009-07-07 Bristol-Myers Squibb Company Thyroid receptor ligands
TW200424214A (en) * 2003-04-21 2004-11-16 Advisys Inc Plasmid mediated GHRH supplementation for renal failures
US7265145B2 (en) 2003-05-28 2007-09-04 Bristol-Myers Squibb Company Substituted piperidines and pyrrolidines as calcium sensing receptor modulators and method
US7459460B2 (en) 2003-05-28 2008-12-02 Bristol-Myers Squibb Company Trisubstituted heteroaromatic compounds as calcium sensing receptor modulators
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
US7361642B2 (en) * 2003-08-04 2008-04-22 Vgx Pharmaceuticals, Inc. Canine specific growth hormone releasing hormone
AU2003272814A1 (en) 2003-10-02 2005-05-19 Ibrahim Al-Habdan Peptide for promoting healing of fractures
EP1711187B1 (en) 2003-12-31 2010-05-12 VGX Pharmaceuticals, LLC Reducing arthritis and lameness in subjects by growth hormone releasing hormone (ghrh) supplementation
ATE507239T1 (de) * 2004-01-20 2011-05-15 VGX Pharmaceuticals LLC Erhöhte sekretion/retention von wachstumshormonfreisetzendem hormon (ghrh) aus muskelzellen durch speziesspezifisches signalpeptid
US20050164952A1 (en) * 2004-01-23 2005-07-28 Vital Pharmaceuticals, Inc. Delivery system for growth hormone releasing peptides
US7820702B2 (en) 2004-02-04 2010-10-26 Bristol-Myers Squibb Company Sulfonylpyrrolidine modulators of androgen receptor function and method
US7378426B2 (en) 2004-03-01 2008-05-27 Bristol-Myers Squibb Company Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3
US7625923B2 (en) 2004-03-04 2009-12-01 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
US7696241B2 (en) 2004-03-04 2010-04-13 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
US9884038B2 (en) 2004-06-07 2018-02-06 University Of Tennessee Research Foundation Selective androgen receptor modulator and methods of use thereof
US9889110B2 (en) 2004-06-07 2018-02-13 University Of Tennessee Research Foundation Selective androgen receptor modulator for treating hormone-related conditions
NZ553274A (en) * 2004-07-23 2010-02-26 VGX Pharmaceuticals LLC Growth hormone releasing hormone enhances the immune response induced by vaccination
AU2005277389A1 (en) 2004-08-18 2006-03-02 Elixir Pharmaceuticals, Inc. Growth-hormone secretagogues
WO2006116401A1 (en) 2005-04-28 2006-11-02 Bristol-Myers Squibb Company C-5 substituted quinazolinone derivatives as selective estrogen receptor beta modulators
AU2006285026B2 (en) 2005-08-31 2012-08-09 University Of Tennessee Research Foundation Treating renal disease, burns, wounds and spinal cord injury with selective androgen receptor modulators
CU23558A1 (es) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
US8058253B2 (en) * 2006-07-06 2011-11-15 Vgx Pharmaceuticals, Inc. Growth hormone releasing hormone treatment to decrease cholesterol levels
PT2038252T (pt) 2006-07-12 2016-12-16 Univ Tennessee Res Found Acilanilidos substituidos e métodos de utilização dos mesmos
US8299248B2 (en) 2006-08-02 2012-10-30 Cytokinetics, Incorporated Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
EP2995619B1 (en) 2006-08-02 2019-09-25 Cytokinetics, Inc. Certain chemical entities comprising imidazopyrimidines, compositions and methods
US9730908B2 (en) 2006-08-24 2017-08-15 University Of Tennessee Research Foundation SARMs and method of use thereof
PL2054049T3 (pl) 2006-08-24 2016-11-30 Podstawione acyloanilidy i sposoby ich stosowania
US10010521B2 (en) 2006-08-24 2018-07-03 University Of Tennessee Research Foundation SARMs and method of use thereof
US9844528B2 (en) 2006-08-24 2017-12-19 University Of Tennessee Research Foundation SARMs and method of use thereof
BRPI0807046A2 (pt) 2007-02-09 2015-05-26 Tranzyme Pharma Inc Composto, composição farmacêutica, métodos de tratar um distúrbio, uma doença cardiovascular e um paciente que sofre de motilidade gastrointestinal reduzida ou disfuncional e, kit.
US20100099640A1 (en) 2007-05-04 2010-04-22 Joannes Geuns Tissue degeneration protection
US7968603B2 (en) 2007-09-11 2011-06-28 University Of Tennessee Research Foundation Solid forms of selective androgen receptor modulators
WO2009155481A1 (en) 2008-06-20 2009-12-23 Gtx, Inc. Metabolites of selective androgen receptor modulators and methods of use thereof
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
WO2011133920A1 (en) 2010-04-23 2011-10-27 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
WO2013190520A2 (en) 2012-06-22 2013-12-27 The General Hospital Corporation Gh-releasing agents in the treatment of vascular stenosis and associated conditions
US9744149B2 (en) 2012-07-13 2017-08-29 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US10314807B2 (en) 2012-07-13 2019-06-11 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US9622992B2 (en) 2012-07-13 2017-04-18 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US9969683B2 (en) 2012-07-13 2018-05-15 Gtx, Inc. Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
US10987334B2 (en) 2012-07-13 2021-04-27 University Of Tennessee Research Foundation Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
US10258596B2 (en) 2012-07-13 2019-04-16 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
MX2015000572A (es) 2012-07-13 2015-09-23 Gtx Inc Metodo para tratar canceres de mama positivos a receptor de androgeno (ar) con modulador de receptor de androgeno selectivo (sarms).
BR112015009107A2 (pt) 2012-10-24 2017-11-14 Daiichi Sankyo Co Ltd agente terapêutico para esclerose lateral amiotrófica, uso de um agonista do receptor do secretagogo do hormônio do crescimento ou um sal farmaceuticamente aceitável do mesmo, e, agonista do receptor do secretagogo do hormônio do crescimento ou sal farmaceuticamente aceitável do mesmo
US10092627B2 (en) 2013-04-08 2018-10-09 President And Fellows Of Harvard College Methods and compositions for rejuvenating skeletal muscle stem cells
US9119832B2 (en) 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
US10328082B2 (en) 2014-05-30 2019-06-25 Pfizer Inc. Methods of use and combinations
WO2017075535A1 (en) 2015-10-28 2017-05-04 Oxeia Biopharmaceuticals, Inc. Methods of treating neurodegenerative conditions
MA56396A (fr) 2019-06-27 2022-05-04 Cytokinetics Inc Polymorphes de 1-(2-((((trans)-3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl)méthyl)amino)pyrimidin-5-yl)-1h-pyrrole-3-carboxamide
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4223021A (en) * 1979-03-30 1980-09-16 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4223019A (en) * 1979-03-30 1980-09-16 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4228157A (en) * 1979-03-30 1980-10-14 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4228158A (en) * 1979-03-30 1980-10-14 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4228155A (en) * 1979-03-30 1980-10-14 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4226857A (en) * 1979-03-30 1980-10-07 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
CA1175810A (en) * 1979-03-30 1984-10-09 Frank A. Momany Synthetic peptides having pituitary growth hormone releasing activity
US4223020A (en) * 1979-03-30 1980-09-16 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4228156A (en) * 1979-03-30 1980-10-14 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4224316A (en) * 1979-03-30 1980-09-23 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4410512A (en) * 1981-12-28 1983-10-18 Beckman Instruments, Inc. Combinations having synergistic pituitary growth hormone releasing activity
US4410513A (en) * 1981-12-28 1983-10-18 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
AU549053B2 (en) * 1981-12-28 1986-01-09 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4880778A (en) * 1986-05-12 1989-11-14 Eastman Kodak Company Combinations having synergistic growth hormone releasing activity and methods for use thereof
US4839344A (en) * 1987-06-12 1989-06-13 Eastman Kodak Company Polypeptide compounds having growth hormone releasing activity
US4880777A (en) * 1987-09-01 1989-11-14 Eastman Kodak Company Synthetic peptides having growth hormone releasing activity
DE68922602T2 (de) * 1988-01-28 1995-12-07 Polygen Holding Corp Polypeptide mit hormonwachstumsbefreiender wirkung.
JPH03502326A (ja) * 1988-01-28 1991-05-30 ポリゲン　ホールディング　コーポレイション 成長ホルモン放出活性を有するポリペプチド化合物類
WO1989010933A1 (en) * 1988-05-11 1989-11-16 Eastman Kodak Company Polypeptide compounds having growth hormone releasing activity
EP0540626A1 (en) 1990-07-24 1993-05-12 Eastman Chemical Company Process for synthesizing peptides
US5486505A (en) * 1990-07-24 1996-01-23 Polygen Holding Corporation Polypeptide compounds having growth hormone releasing activity
IL98910A0 (en) * 1990-07-24 1992-07-15 Polygen Holding Corp Polypeptide compounds having growth hormone releasing activity and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
BR9206398A (pt) 1994-12-27
BG62655B1 (bg) 2000-04-28
FI20050467A (fi) 2005-05-02
FI940807A0 (fi) 1994-02-21
ATE172742T1 (de) 1998-11-15
CN1073684A (zh) 1993-06-30
NZ244034A (en) 1995-08-28
JP3179489B2 (ja) 2001-06-25
DE69227462T2 (de) 1999-04-08
US5663146A (en) 1997-09-02
RO112507B1 (ro) 1997-10-30
AU666673B2 (en) 1996-02-22
SK20494A3 (en) 1994-10-05
ES2124263T3 (es) 1999-02-01
KR100247212B1 (ko) 2000-03-15
AU2541692A (en) 1993-03-16
CA2116120C (en) 2002-12-03
EP0605484B1 (en) 1998-10-28
HU223664B1 (hu) 2004-11-29
BR1100309A (pt) 2000-08-01
IL102848A0 (en) 1993-01-31
ZA926337B (en) 1993-04-22
NO314695B1 (no) 2003-05-05
CZ40094A3 (en) 1994-11-16
US5776901A (en) 1998-07-07
WO1993004081A1 (en) 1993-03-04
JPH07507039A (ja) 1995-08-03
SK282895B6 (sk) 2003-01-09
FI120095B (fi) 2009-06-30
EP0605484A1 (en) 1994-07-13
NO940592L (no) 1994-04-14
CZ293281B6 (cs) 2004-03-17
RU2126014C1 (ru) 1999-02-10
CN1035256C (zh) 1997-06-25
CA2116120A1 (en) 1993-02-23
BG98489A (bg) 1995-02-28
FI120691B (fi) 2010-01-29
NO940592D0 (no) 1994-02-21
DK0605484T3 (da) 1999-07-05
PL169562B1 (pl) 1996-08-30
MX9204861A (es) 1994-06-30
IL102848A (en) 1998-04-05
HU9400495D0 (en) 1994-05-30
HUT69178A (en) 1995-08-28
DE69227462D1 (de) 1998-12-03

Similar Documents

Publication Publication Date Title
FI940807A (fi) Peptidejä, joilla on kasvuhormonia vapauttavaa aktiivisuutta
NO884408L (no) Kontrollerte frigjoeringsformuleringer av tetracyklinforbindelser.
RS20090086A (en) Nucleoside analogs with carobxamidine modified monocyclic base
ATE82121T1 (de) Arzneimittel fuer die therapeutische behandlung von alopezie.
MX163592B (es) Compuestos de polipeptido que tienen actividad liberadora de la hormona del crecimiento
NO165237C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive benzensulfonamido-indanylforbindelser.
LV11985A (lv) Noteiktu cistina atvasinajumu farmakologiska izmantosana
FI930261A0 (fi) Polypeptidfoereningar som har vaexthormon frigoerande verkan
NO165916C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive, ikke-aromatiske fluorallylamin mao-inhibitorer.
IT1149234B (it) Procedimento per la preparazione di peptidi aciclici aventi attivita' terapeutica
NO167144C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktiv imidazo (4,5-f) isokinolin-2-on.
NO167381C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktiv (e)-2-(p-fluorfenethyl)-3-fluorallylamin.
SU1578880A1 (ru) Пептид, обладающий защитным действием против вируса ящура штамма a
NO871195L (no) Analogifremgangsmaate for fremstilling av terapeutisk aktiv 1-cyklopropyl-6-fluor-1,4-dihydro-4-okso-7-piperazino kinolin-3-karboksylsyre.
NO912745D0 (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 1,2,5,6-tetrahydropyridinforbindelser.
SU1354461A1 (ru) Метиловый эфир 3-бром-4-(4-бромфенил)-2-дифенилметокси-4-оксо-2-бутеновой кислоты, проявляющий противостафилококковую активность
NO164479C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive peptidforbindelser.
SU1363769A1 (ru) Метиловый эфир 4-дифенилметилиденгидразино-2-оксо-4-фенил-3-бутеновой кислоты, проявляющий противовоспалительную активность
NO912746L (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive kinuklidinforbindelser.

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 120095

Country of ref document: FI

MM Patent lapsed